NEW YORK--(BUSINESS WIRE)--
Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Insys Therapeutics, Inc. (INSY) resulting from allegations that Insys may have issued materially misleading business information to the investing public.
On March 15, 2017, Insys disclosed during aftermarket hours that it would delay the release of its financial results for the fourth quarter and full year 2016 in order to complete an independent review of its processes related to certain sales allowances and extended payment terms, which could result in a reduction of 2015 net revenue and pre-tax income. Insys further disclosed that it would not timely file its 2016 annual financial statements. On this news, shares of Insys fell $0.49 per share or approximately 5% to close at $10.06 per share on March 16, 2017.
Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Insys investors. If you purchased shares of Insys please visit the firm’s website at http://www.rosenlegal.com/cases-1087.html for more information. You may also contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at firstname.lastname@example.org or email@example.com.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Attorney Advertising. Prior results do not guarantee a similar outcome.